NanoViricides says Phase IIa Ebola trial of NV-387 oral gummies progresses well
NNVC•NanoViricides said its Phase IIa trial of NV-387 oral gummies for Bundibugyo Ebola in the Democratic Republic of the Congo is progressing. No results have been presented; a safety and tolerability update is expected after the trial ends and investigators complete a report.
1. Trial progress
NanoViricides said its Phase IIa trial of NV-387 oral gummies for Bundibugyo Ebola in the Democratic Republic of the Congo is progressing. The study aims to identify a workable dosing regimen for very ill patients, with treatment stopped when testing shows no detectable virus.
2. Next study
The trial is not designed to produce statistically powered efficacy results, though management expects any strong benefit could still be apparent. A selected regimen would move to a larger randomized, controlled Phase IIb study to evaluate effectiveness.
